NeoVentures Biotechnology Europe
Entity
Description
  • Value proposition

    Aptamarker Platform | High-Plex Proteomics | Biomarker Discovery | Advanced DNA Aptamer Library & Machine Learning

    At NeoVentures Biotechnology Europe we are committed to revolutionizing the biopharmaceutical field through a cutting-edge biomarker discovery platform, propelling the industry towards personalized medicine with rapid, cost-effective, and automated processes for biomarker discovery and validation. Our Aptamarker platform leverages a library of 16.8 million DNA aptamers to analyze epitope profiles in biofluids, liquid biopsy or tissue, facilitating the precise measurement of surrogate biomarkers and expediting the creation of predictive In Vitro Diagnostic (IVD) tests tailored to distinct pathophysiological conditions. With our advanced DNA aptamer libraries and machine learning algorithms, we meticulously screen an extensive array of 16.8 million DNA aptamer-epitope interactions, uncovering intricate molecular complexities, including proteins and macromolecular complexes. Collaborating with us means embarking on projects to identify or validate biomarkers tailored to your specific needs, whether it's predicting side effects in therapeutic treatments, assessing treatment responses, stratifying patients within a pathology on a molecular level (canonical or non-canonical forms of proteins), or mapping target engagement. The Aptamarkers identified through our collaboration will be readily available to you for further commercial development in a qPCR format. Join us in leading high-plex proteomics innovation to shape the future of clinical diagnostic applications.

    biotechnology, Alzheimer's, biomarkers, blood diagnosis, pathology detection, aptamers, and proteomics

  • Original language

    Aptamarker Platform | High-Plex Proteomics | Biomarker Discovery | Advanced DNA Aptamer Library & Machine Learning

    At NeoVentures Biotechnology Europe we are committed to revolutionizing the biopharmaceutical field through a cutting-edge biomarker discovery platform, propelling the industry towards personalized medicine with rapid, cost-effective, and automated processes for biomarker discovery and validation. Our Aptamarker platform leverages a library of 16.8 million DNA aptamers to analyze epitope profiles in biofluids, liquid biopsy or tissue, facilitating the precise measurement of surrogate biomarkers and expediting the creation of predictive In Vitro Diagnostic (IVD) tests tailored to distinct pathophysiological conditions. With our advanced DNA aptamer libraries and machine learning algorithms, we meticulously screen an extensive array of 16.8 million DNA aptamer-epitope interactions, uncovering intricate molecular complexities, including proteins and macromolecular complexes. Collaborating with us means embarking on projects to identify or validate biomarkers tailored to your specific needs, whether it's predicting side effects in therapeutic treatments, assessing treatment responses, stratifying patients within a pathology on a molecular level (canonical or non-canonical forms of proteins), or mapping target engagement. The Aptamarkers identified through our collaboration will be readily available to you for further commercial development in a qPCR format. Join us in leading high-plex proteomics innovation to shape the future of clinical diagnostic applications.

  • NeoVentures Biotechnology Europe | Aptamarker Platform

    NeoVentures Biotechnology Europe has developed the Aptamarker Platform, the next generation of biomarker discovery in the high-plex proteomics space.

    • https://neoventures-eu.com/
Corporate interactions BETA
Corporate TypeTweets Articles
Medicen Paris Region
Medicen Paris Region
Public business cluster, French Cluster, Civic and Social Organizations
Medicen Paris Region
Public business cluster, French Cluster, Civic and Social Organizations 		Other

8 Dec 2022


Similar entities
Last news
Show all articles
Social network dynamics